Appili Therapeutics APLIF Stock
Appili Therapeutics Price Chart
Appili Therapeutics APLIF Financial and Trading Overview
| Appili Therapeutics stock price | 0.03 USD |
| Previous Close | 0.02 USD |
| Open | 0.02 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.02 - 0.02 USD |
| 52 Week Range | 0.02 - 0.08 USD |
| Volume | 500 USD |
| Avg. Volume | 22.52K USD |
| Market Cap | 3.19M USD |
| Beta (5Y Monthly) | 1.015964 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.03 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.23 USD |
APLIF Valuation Measures
| Enterprise Value | 6.8M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.38333336 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | Infinity |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.901 |
Trading Information
Appili Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.015964 |
| 52-Week Change | -54.90% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.08 USD |
| 52 Week Low | 0.02 USD |
| 50-Day Moving Average | 0.03 USD |
| 200-Day Moving Average | 0.04 USD |
APLIF Share Statistics
| Avg. Volume (3 month) | 22.52K USD |
| Avg. Daily Volume (10-Days) | 11.05K USD |
| Shares Outstanding | 121.27M |
| Float | 91.75M |
| Short Ratio | N/A |
| % Held by Insiders | 12.43% |
| % Held by Institutions | 12.03% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | March 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -67.70% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | -99.29% |
| Gross Profit (ttm) | 1.39M USD |
| EBITDA | -7547579 USD |
| Net Income Avi to Common (ttm) | -9915818 USD |
| Diluted EPS (ttm) | -0.08 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.43M USD |
| Total Cash Per Share (mrq) | 0.01 USD |
| Total Debt (mrq) | 5.44M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.988 |
| Book Value Per Share (mrq) | -0.044 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12852020 USD |
| Levered Free Cash Flow (ttm) | -10369862 USD |
Profile of Appili Therapeutics
| Country | United States |
| State | NS |
| City | Halifax |
| Address | #21-1344 Summer Street |
| ZIP | B3H 0A8 |
| Phone | N/A |
| Website | https://www.appilitherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 8 |
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Q&A For Appili Therapeutics Stock
What is a current APLIF stock price?
Appili Therapeutics APLIF stock price today per share is 0.03 USD.
How to purchase Appili Therapeutics stock?
You can buy APLIF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Appili Therapeutics?
The stock symbol or ticker of Appili Therapeutics is APLIF.
Which industry does the Appili Therapeutics company belong to?
The Appili Therapeutics industry is Biotechnology.
How many shares does Appili Therapeutics have in circulation?
The max supply of Appili Therapeutics shares is 122.67M.
What is Appili Therapeutics Price to Earnings Ratio (PE Ratio)?
Appili Therapeutics PE Ratio is now.
What was Appili Therapeutics earnings per share over the trailing 12 months (TTM)?
Appili Therapeutics EPS is -0.03 USD over the trailing 12 months.
Which sector does the Appili Therapeutics company belong to?
The Appili Therapeutics sector is Healthcare.